{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T05:30:12Z","timestamp":1738474212471,"version":"3.35.0"},"reference-count":18,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T00:00:00Z","timestamp":1732147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16ck0106129","JP19ck0106331","JP22ck0106607","JP24ck0106851"],"award-info":[{"award-number":["JP16ck0106129","JP19ck0106331","JP22ck0106607","JP24ck0106851"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the effectiveness and safety of nelarabine (NEL)\u2010combined chemotherapy for newly diagnosed adult T\u2010cell acute lymphoblastic leukemia (T\u2010ALL) patients. We conducted a phase II trial, T\u2010ALL213\u2010O, where adult T\u2010ALL patients aged 25 to 64 were treated by a regimen based on that used in our previous study, ALL202\u2010O. The main modifications from ALL202\u2010O to T\u2010ALL213\u2010O were as follows: (1) NEL\u2010combined chemotherapy, instead of consolidation (C)1, was used for non\u2010complete remission (CR) patients after induction therapy (IND)1 as IND2; (2) NEL treatments were inserted into C3 and C5 on day 29. Twenty\u2010four patients were analyzed. Ten patients did not receive NEL treatment due to therapy termination prior to C3. Three\u2010year event\u2010free survival (EFS) was 70%, with 52% as the lower limit of its 90% confidence interval, which exceeded the threshold of 25%; thus, the study treatment was considered effective. The CR rates by IND1, IND2, and both were 75%, 100%, and 88%, respectively. The 5\u2010year EFS and 5\u2010year overall survival rates were 66% and 70%, respectively, with median follow\u2010ups of 7.7 and 7.8\u2009years. The addition of NEL improved the CR rate but not survival, compared with T\u2010ALL patients in ALL202\u2010O. Severe neuropathy after NEL administration was observed at a high frequency. Seven (50%) of 14 patients treated with NEL showed grade 3 peripheral neuropathy and\/or gait disturbance. The neurotoxicity was considered stronger than that previously reported. Combination therapy of NEL at this dose and intensive multidrug chemotherapy is associated with a high risk of severe neurotoxicity (JALSG T\u2010ALL213\u2010O, UMIN000010642).<\/jats:p>","DOI":"10.1111\/cas.16405","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:40:08Z","timestamp":1732236008000},"page":"453-461","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nelarabine\u2010combined chemotherapy improves outcome of T\u2010cell acute lymphoblastic leukemia but shows more severe neurotoxicity: <scp>JALSG<\/scp> T\u2010<scp>ALL213<\/scp>\u2010O"],"prefix":"10.1111","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6067-6382","authenticated-orcid":false,"given":"Fumihiko","family":"Hayakawa","sequence":"first","affiliation":[{"name":"Division of Cellular and Genetic Sciences, Department of Integrated Health Sciencies Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Preventive Medicine International University of Health and Welfare  Narita Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyotoshi","family":"Imai","sequence":"additional","affiliation":[{"name":"Sapporo Fuji Clinic  Sapporo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhisa","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Department of Hematology University of Tsukuba  Tsukuba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Katsuoka","sequence":"additional","affiliation":[{"name":"Department of Hematology NHO Sendai Medical Center  Sendai Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology\/Hematology The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tohru","family":"Murayama","sequence":"additional","affiliation":[{"name":"Department of Hematology Hyogo Cancer Center  Akashi Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology Yokohama Rosai Hospital  Yokohama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[{"name":"Japanese Data Center for Hematopoietic Cell Transplantation  Nagakute Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Sakaida","sequence":"additional","affiliation":[{"name":"Department of Hematology Chiba University Hospital  Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[{"name":"Division of Hematology and Rheumatology Nihon University School of Medicine  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itaru","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology Kindai University School of Medicine  Osaka Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-7147","authenticated-orcid":false,"given":"Yasushi","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology and Molecular Medicine Unit, Atomic Bomb Disease Institute Nagasaki University Graduate School of Biomedical Sciences  Nagasaki Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology Nagoya University Graduate School of Medicine  Nagoya Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Japan Adult Leukemia Study Group (JALSG)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,11,21]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2017.08.006"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-231217"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6768"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.4084\/MJHID.2024.031"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1262757"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24947"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00256"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00072-8"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","unstructured":"RowntreeCJ KirkwoodAA HadleyLC et\u00a0al.First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T\u2010cell acute lymphoblastic leukaemia (CRUK\/09\/006).63rd ASH Annual Meeting Abstracts.2021.","DOI":"10.1182\/blood-2021-152355"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","unstructured":"GoekbugetN FiedlerW AlakelN et\u00a0al.Results of the risk\u2010adapted MRD\u2010Stratifed GMALL Trial 08\/2013 in 281 T\u2010ALL\/T\u2010Lbl patients: excellent outcome of standard risk thymic T\u2010ALL.64th ASH Annual Meeting Abstracts.2022.","DOI":"10.1182\/blood-2022-158381"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-010-0672-z"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1389"},{"key":"e_1_2_11_15_1","first-page":"79","article-title":"Effectiveness of high\u2010dose MTX therapy for adult Ph\u2010negative ALL by randomized trial: JALSG ALL202\u2010O","volume":"126","author":"Sakura T","year":"2015","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0925-5710(98)00075-9"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402526"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116186"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","unstructured":"HattaY SatoA KadaA et\u00a0al.Risk stratifed therapy with nelarabine and intensifed administration of L\u2010asparaginase for newly diagnosed T\u2010cell acute lymphoblastic leukemia in adolescents and young adults (JPLSG T\u201011\/JALSG T\u2010ALL\u2010211\u2010U): An intergroup phase 2 study.64th ASH Annual Meeting Abstracts.2022.","DOI":"10.1182\/blood-2022-156613"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.16405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:45:17Z","timestamp":1738417517000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.16405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,21]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/cas.16405"],"URL":"https:\/\/doi.org\/10.1111\/cas.16405","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"type":"print","value":"1347-9032"},{"type":"electronic","value":"1349-7006"}],"subject":[],"published":{"date-parts":[[2024,11,21]]},"assertion":[{"value":"2024-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}